CAPR (Capricor Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)

What is Capricor Therapeutics OCF Margin %?

Capricor Therapeutics CAPR -0.34% 37 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates CAPR with a GF Score™ of 37/100 and a GF Value™ of $4.87 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Capricor Therapeutics ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Capricor Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-29.26 Mil. Capricor Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Capricor Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Capricor Therapeutics's current OCF Yield % is -5.42%.

The historical rank and industry rank for Capricor Therapeutics's OCF Margin % or its related term are showing as below:

During the past 13 years, the highest OCF Margin % of Capricor Therapeutics was 192.75%. The lowest was -6860.82%. And the median was -533.80%.

CAPR's OCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Capricor Therapeutics OCF Margin % Related Terms

Capricor Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics OCF Margin % Chart

Capricor Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

-6,860.82

192.75

-101.66

-179.60

0.00

Capricor Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
OCF Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

37GF Score

Capricor Therapeutics Inc CAPR

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Capricor Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Capricor Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-69.811	/	0
	=	%

Capricor Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-29.255	/	0
	=	%

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of 0.00% mean?

Capricor Therapeutics (CAPR) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Capricor Therapeutics and its competitors. According to the industry distribution chart, Capricor Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.

Is Capricor Therapeutics' OCF Margin % too high?

Capricor Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Capricor Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Capricor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Capricor Therapeutics' OCF Margin % compare to SNDX and SLS?

According to the Biotechnology industry distribution chart, Capricor Therapeutics ranks #999999 out of 959 companies for OCF Margin %. This places Capricor Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Capricor Therapeutics and its competitors. Capricor Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Capricor Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Capricor Therapeutics (CAPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.87, compared to a current price of $29.50 — trading 505.7% above its estimated fair value. The current OCF Margin % is 0.00%. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Capricor Therapeutics (CAPR) Overvalued in 2026?

Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued. The current stock price of $29.50 is trading 505.7% above its estimated GF Value™ of $4.87. GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.

Key valuation signals for CAPR:

OCF Margin %: 0.00%
GF Value™: $4.87 vs. price of $29.50 (505.7% above fair value)
GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Capricor Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies SNDX SLS AGIO VCEL PVLA TSHA GENB QURE ATAI NVAX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 4LN2:Germany

Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121

Website https://www.capricor.com

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

37GF Score

Get the complete analysis for CAPR

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.50

Price

$4.87

GF Value

View CAPR Analysis

See OCF Margin % data for all stocks →